Towards a vaccine for Cryptococcus neoformans

Principles and caveats

Kausik Datta, Liise-anne Pirofski

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated from a latent state. Hence, a vaccine for C. neoformans would need to prevent disease resulting from either acute or reactivated infection. The evidence to support the development of a vaccine for C. neoformans that induces antibody-mediated immunity is discussed herein.

Original languageEnglish (US)
Pages (from-to)525-536
Number of pages12
JournalFEMS Yeast Research
Volume6
Issue number4
DOIs
StatePublished - Jun 2006

Fingerprint

Cryptococcus neoformans
Vaccines
Communicable Diseases
Virulence
Immunity
Antibodies
Infection

Keywords

  • Antibody-mediated immunity
  • Cryptococcus neoformans
  • Vaccine

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Infectious Diseases

Cite this

Towards a vaccine for Cryptococcus neoformans : Principles and caveats. / Datta, Kausik; Pirofski, Liise-anne.

In: FEMS Yeast Research, Vol. 6, No. 4, 06.2006, p. 525-536.

Research output: Contribution to journalArticle

@article{8d5e703d623b44679a7a48f3f35df7b2,
title = "Towards a vaccine for Cryptococcus neoformans: Principles and caveats",
abstract = "In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated from a latent state. Hence, a vaccine for C. neoformans would need to prevent disease resulting from either acute or reactivated infection. The evidence to support the development of a vaccine for C. neoformans that induces antibody-mediated immunity is discussed herein.",
keywords = "Antibody-mediated immunity, Cryptococcus neoformans, Vaccine",
author = "Kausik Datta and Liise-anne Pirofski",
year = "2006",
month = "6",
doi = "10.1111/j.1567-1364.2006.00073.x",
language = "English (US)",
volume = "6",
pages = "525--536",
journal = "FEMS Yeast Research",
issn = "1567-1356",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Towards a vaccine for Cryptococcus neoformans

T2 - Principles and caveats

AU - Datta, Kausik

AU - Pirofski, Liise-anne

PY - 2006/6

Y1 - 2006/6

N2 - In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated from a latent state. Hence, a vaccine for C. neoformans would need to prevent disease resulting from either acute or reactivated infection. The evidence to support the development of a vaccine for C. neoformans that induces antibody-mediated immunity is discussed herein.

AB - In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated from a latent state. Hence, a vaccine for C. neoformans would need to prevent disease resulting from either acute or reactivated infection. The evidence to support the development of a vaccine for C. neoformans that induces antibody-mediated immunity is discussed herein.

KW - Antibody-mediated immunity

KW - Cryptococcus neoformans

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33646568758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646568758&partnerID=8YFLogxK

U2 - 10.1111/j.1567-1364.2006.00073.x

DO - 10.1111/j.1567-1364.2006.00073.x

M3 - Article

VL - 6

SP - 525

EP - 536

JO - FEMS Yeast Research

JF - FEMS Yeast Research

SN - 1567-1356

IS - 4

ER -